Maarten G Lansberg, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lansberg’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A75890 · Current
Licensed to practise in California · since 2001 · expires 2027-03-31 · University of Utrecht Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$25,794
Medicare paid this office $25,794 for 143 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $6,813 | $106 |
| Long return visit (40+ min) | 33 | $4,024 | $109 |
| New patient visit (60+ min) | 24 | $3,671 | $153 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,645 | $147 |
| Complete ultrasound of within the brain blood flow | 16 | $2,422 | $42 |
See all 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $6,813 | $106 |
| Long return visit (40+ min) | 33 | $4,024 | $109 |
| New patient visit (60+ min) | 24 | $3,671 | $153 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,645 | $147 |
| Complete ultrasound of within the brain blood flow | 16 | $2,422 | $42 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,469 | $105 |
Who their Medicare patients are
143 Original Medicare patients in 2024. Average age 78 · Women 57% · Also on Medicaid 25% · Health risk score 1.89. Above the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Stroke 75% · Diabetes 44% · Coronary heart disease 41% · Atrial fibrillation 34% · Chronic kidney disease 33% · Depression 28% · Heart failure 26% · Dementia 22% · Cancer 19% · COPD 12%.
The office billed $144,938, Medicare allowed $33,975 and paid $25,794; for 257 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 143 | 257 | 78 | 1.89 | $144,938 | $25,794 |
| 2023 | 199 | 417 | 78 | 1.60 | $205,195 | $43,563 |
| 2022 | 153 | 279 | 78 | 1.62 | $130,562 | $27,794 |
| 2021 | 204 | 433 | 77 | 1.67 | $183,170 | $41,582 |
| 2020 | 146 | 256 | 76 | 1.96 | $111,446 | $26,446 |
| 2019 | 183 | 382 | 77 | 1.84 | $145,048 | $33,756 |
| 2018 | 152 | 284 | 76 | 1.75 | $110,309 | $27,294 |
| 2017 | 190 | 407 | 76 | 1.81 | $153,021 | $36,051 |
| 2016 | 214 | 396 | 76 | 1.87 | $151,624 | $38,271 |
| 2015 | 200 | 416 | 77 | 1.67 | $185,784 | $43,717 |
| 2014 | 175 | 353 | 77 | 1.79 | $167,624 | $37,482 |
| 2013 | 199 | 456 | 75 | 1.74 | $205,876 | $44,018 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $12,203 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 71 | $11,355 | $160 |
| Long return visit (40+ min) | 53 | $7,580 | $133 |
| Complete ultrasound of within the brain blood flow | 21 | $3,703 | $39 |
| Hospital discharge day management, more than 30 minutes | 33 | $3,534 | $107 |
| New patient visit (60+ min) | 17 | $2,505 | $147 |
2022: 7 services
| Long return visit (40+ min) | 39 | $5,484 | $117 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $5,240 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $4,994 | $89 |
| New patient visit (60+ min) | 26 | $4,291 | $165 |
| Complete ultrasound of within the brain blood flow | 15 | $2,863 | $43 |
| Hospital discharge day management, more than 30 minutes | 16 | $1,571 | $98 |
| Return visit (30+ min) | 11 | $898 | $82 |
2021: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $10,692 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $7,818 | $186 |
| Long return visit (40+ min) | 38 | $6,143 | $128 |
| Complete ultrasound of within the brain blood flow | 31 | $4,613 | $43 |
| Hospital discharge day management, more than 30 minutes | 38 | $3,765 | $97 |
| New patient visit (60+ min) | 16 | $2,794 | $175 |
| Return visit (30+ min) | 20 | $1,624 | $77 |
2020: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $6,183 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,481 | $203 |
| Hospital discharge day management, more than 30 minutes | 30 | $3,005 | $100 |
| New patient visit (60+ min) | 14 | $2,406 | $172 |
| Long return visit (40+ min) | 22 | $2,349 | $107 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,859 | $133 |
| Return visit (30+ min) | 18 | $1,329 | $74 |
| Complete ultrasound of within the brain blood flow | 13 | $1,033 | $43 |
2019: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $10,282 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,772 | $184 |
| New patient visit (60+ min) | 32 | $4,548 | $142 |
| Long return visit (40+ min) | 37 | $3,635 | $96 |
| Complete ultrasound of within the brain blood flow | 22 | $3,495 | $42 |
| Hospital discharge day management, more than 30 minutes | 28 | $2,975 | $99 |
| Return visit (30+ min) | 13 | $789 | $56 |
2018: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $7,490 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,750 | $179 |
| Long return visit (40+ min) | 33 | $3,125 | $87 |
| New patient visit (60+ min) | 19 | $2,860 | $151 |
| Complete ultrasound of within the brain blood flow | 15 | $2,282 | $41 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,876 | $99 |
| New patient visit (60+ min) | 12 | $1,806 | $151 |
| Long return visit (40+ min) | 17 | $1,696 | $100 |
2017: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $9,068 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,076 | $181 |
| Complete ultrasound of within the brain blood flow | 23 | $4,765 | $42 |
| Long return visit (40+ min) | 41 | $4,134 | $92 |
| New patient visit (60+ min) | 19 | $2,855 | $150 |
| Hospital discharge day management, more than 30 minutes | 24 | $2,357 | $98 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,952 | $122 |
| Return visit (30+ min) | 13 | $1,058 | $62 |
2016: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $9,166 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $5,098 | $176 |
| Hospital discharge day management, more than 30 minutes | 42 | $4,019 | $96 |
| Long return visit (40+ min) | 36 | $3,865 | $97 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,187 | $121 |
| New patient visit (60+ min) | 15 | $2,123 | $142 |
| Initial hospital observation care per day, typically 70 minutes | 12 | $1,983 | $165 |
| Complete ultrasound of within the brain blood flow | 19 | $1,950 | $42 |
| New patient visit (60+ min) | 13 | $1,816 | $140 |
| Return visit (30+ min) | 17 | $1,300 | $68 |
2015: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $12,565 | $93 |
| Critical care, first 30-74 minutes | 19 | $5,674 | $196 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,026 | $180 |
| Hospital discharge day management, more than 30 minutes | 39 | $3,810 | $98 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $3,418 | $122 |
| Long return visit (40+ min) | 32 | $3,230 | $87 |
| Return visit (30+ min) | 24 | $1,684 | $65 |
| New patient visit (60+ min) | 11 | $1,649 | $150 |
| Complete ultrasound of within the brain blood flow | 18 | $1,311 | $42 |
2014: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $9,242 | $92 |
| Critical care, first 30-74 minutes | 23 | $7,428 | $195 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,576 | $180 |
| Long return visit (40+ min) | 23 | $2,664 | $95 |
| Hospital discharge day management, more than 30 minutes | 26 | $2,510 | $97 |
| New patient visit (60+ min) | 16 | $2,316 | $145 |
| Return visit (30+ min) | 24 | $1,874 | $69 |
| Complete ultrasound of within the brain blood flow | 23 | $1,709 | $44 |
2013: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $11,833 | $90 |
| Critical care, first 30-74 minutes | 27 | $8,369 | $190 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $7,697 | $175 |
| Complete ultrasound of within the brain blood flow | 31 | $4,290 | $41 |
| New patient visit (60+ min) | 24 | $3,368 | $140 |
| Long return visit (40+ min) | 32 | $3,128 | $89 |
| Hospital discharge day management, more than 30 minutes | 21 | $1,991 | $95 |
| Return visit (30+ min) | 17 | $1,020 | $60 |
Drugs they prescribed that Part D paid
$1,457
Pharmacies billed $1,457 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 63) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
63 generic and 0 brand-name prescriptions · $1,457 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Cilostazol | 16 | $847 | $53 |
| Amlodipine Besylate | 15 | $118 | $8 |
Year by year
| 2024 | 63 | 19 | 0% (0) | 0% | $1,457 |
| 2023 | 55 | 19 | 0% (0) | 0% | $1,379 |
| 2022 | 57 | 22 | 0% (0) | 19% | $6,406 |
| 2021 | 75 | 28 | 0% (0) | 23% | $17,681 |
| 2020 | 82 | 23 | 0% (0) | 13% | $13,674 |
| 2019 | 86 | 23 | 0% (0) | None | $6,777 |
| 2018 | 60 | 18 | 0% (0) | None | $4,388 |
| 2017 | 121 | 25 | 0% (0) | 29% | $13,110 |
| 2016 | 186 | 40 | 0% (0) | 17% | $15,572 |
| 2015 | 164 | 37 | 0% (0) | 12% | $10,610 |
| 2014 | 130 | 28 | 0% (0) | 18% | $9,116 |
| 2013 | 120 | 25 | 0% (0) | 13% | $9,852 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Cilostazol | 14 | $762 | $54 |
2022: 1 drug
| Clopidogrel | 19 | $354 | $19 |
2021: 1 drug
| Clopidogrel | 13 | $289 | $22 |
2020: 3 drugs
| Atorvastatin | 19 | $324 | $17 |
| Clopidogrel | 14 | $162 | $12 |
| Hydrochlorothiazide | 12 | $32 | $3 |
2019: 2 drugs
| Atorvastatin | 26 | $390 | $15 |
| Clopidogrel | 21 | $131 | $6 |
2018: 1 drug
| Atorvastatin | 20 | $394 | $20 |
2017: 3 drugs
| Midodrine | 14 | $1,261 | $90 |
| Atorvastatin | 36 | $398 | $11 |
| Clopidogrel | 19 | $257 | $14 |
2016: 4 drugs
| Xarelto | 12 | $4,366 | $364 |
| Clopidogrel | 59 | $599 | $10 |
| Atorvastatin | 33 | $556 | $17 |
| Lamotrigine | 11 | $121 | $11 |
2015: 4 drugs
| Midodrine | 11 | $737 | $67 |
| Clopidogrel | 55 | $405 | $7 |
| Atorvastatin | 29 | $365 | $13 |
| Lamotrigine | 13 | $159 | $12 |
2014: 3 drugs
| Clopidogrel | 37 | $552 | $15 |
| Atorvastatin | 25 | $394 | $16 |
| Lamotrigine | 11 | $155 | $14 |
2013: 3 drugs
| Atorvastatin | 18 | $594 | $33 |
| Clopidogrel | 26 | $469 | $18 |
| Hydrochlorothiazide | 13 | $42 | $3 |
Money from drug and device companies
$20,355 in 2023
| 2023 | 1 | 1 | $20,355 | $20,355 |
| 2022 | 2 | 2 | $43,470 | $43,805 |
| 2021 | 1 | 1 | $2,040 | $2,040 |
| 2020 | 1 | 2 | $17,825 | $17,995 |
| 2019 | 1 | 4 | $1,767 | $1,767 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech | None | $20,355 | 1 payment
|
See the published payment
| Genentech | Consulting · 2023-02-09 | None | $20,355 |
See earlier years (2022, 2021, 2020, 2019)
2022: $43,805
| Genentech | Activase | $43,470 | 1 payment
|
| Viz.ai | Viz.Ai Lvo | $335 | 1 payment
|
2021: $2,040
| Novo Nordisk AS | None | $2,040 | 1 payment
|
2020: $17,995
| Genentech | Activase | $17,995 | 2 payments
|
2019: $1,767
| F. Hoffmann-La Roche AG | Activase | $1,767 | 4 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Biogen, Inc. · Phase 3 Study To Evaluate the Efficacy and Safety of Intravenous Biib093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction · 2019 | This clinician | $31,965 |
| F. Hoffmann-La Roche AG · Tenecteplase in Stroke Patients Between 4 5 and 24 Hours · 2024 | This clinician | $1,103 |
| F. Hoffmann-La Roche AG · Efficacy and Safety of Tenecteplase in Patients With Late-Window Acute Ischaemic Stroke and Evidence of Salvageable Tissue: Results From the Phase III Timeless Trial · 2023 | This clinician | $687 |
| F. Hoffmann-La Roche AG · Efficacy and Safety of Tenecteplase in Patients With Late-Window Acute Ischemic Stroke and Evidence of Salvageable Tissue: Results From the Phase 3 Timeless Trial · 2023 | This clinician | $362 |
| Novo Nordisk AS · 2019 | This clinician | $200 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1275690430
- Licence
- CA A75890California A75890: Current · expires 2027-03-31
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A758900
- Taxonomy
- Federal specialty code 2084V0102X (2084V0102X); Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94305
- NPI first listed
- 2007-01-03
- NPI last updated
- 2023-11-09
- NPI record certified
- 2023-11-09
This is when the NPI record was last certified, not a medical board exam.